• Converted about $1.22 million of a Feb. 16, 2024 Promissory Note into 5,065,840 common shares via exchange agreements dated Aug. 31-Sep. 3, 2026.
• Average conversion price about $0.24 per share; Promissory Note satisfied in full as of Sep. 3, 2026.
• Shares issued under Securities Act Section 3(a)(9) exemption as an unregistered exchange with an existing holder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-041537), on September 04, 2026, and is solely responsible for the information contained therein.